DAT (chemotherapy)

DAT
Specialty	oncology

DAT in the context of chemotherapy is an acronym that means a chemotherapy regimen most often used as an induction regimen in acute myelogenous leukemia, usually for those who are refractory to the standard "7+3" induction regimen or who has relapsed. But this regimen also can be used as primary, first-line induction therapy.

The DAT regimen consists of:

(D)aunorubicin - an anthracycline antibiotic that is able to intercalate DNA, thus disrupting cell division and preventing mitosis;
(A)ra-C (cytarabine) - an antimetabolite;
(T)hioguanine - another antimetabolite.[1]

Dosing regimen

Drug	Dose	Mode	Days
Ara-C (cytarabine)	200 mg/m²	IV push every 12 hours in 2 divided doses (100 mg/m² each)	Days 1-10
Daunorubicin	50 mg/m²	IV slow push	Days 1, 3 and 5
Thioguanine	200 mg/m²	PO every 12 hours in 2 divided doses (100 mg/m² each)	Days 1-10

References

Randomized Comparison of DAT Versus ADE as Induction Chemotherapy in Children and Younger Adults With Acute Myeloid Leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Randomized Comparison of DAT Versus ADE as Induction Chemotherapy in Children and Younger Adults With Acute Myeloid Leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10)